Synapse - Molecular predictors and current management of minimal residual disease (MRD) following induction chemotherapy for acute myeloid leukemia (AML)

Molecular predictors and current management of minimal residual disease (MRD) following induction chemotherapy for acute myeloid leukemia (AML) Meeting Abstract

Authors:	Goldberg, A. D.; Famulare, C.; Devlin, S. M.; Farnoud, N.; Menghrajani, K.; Patel, M.; Cai, S.; Dunbar, A.; Epstein-Peterson, Z. D.; McGovern, E.; Schulman, J.; Glass, J. L.; Taylor, J.; Viny, A. D.; Getta, B.; Arcila, M. E.; Levine, R. L.; Shaffer, B. C.; Gyurkocza, B.; Papadopoulos, E. B.; Perales, M. A.; Papaemmanuil, E.; Giralt, S.; Zhang, Y.; Roshal, M.; Tallman, M. S.
Abstract Title:	Molecular predictors and current management of minimal residual disease (MRD) following induction chemotherapy for acute myeloid leukemia (AML)
Meeting Title:	60th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	132
Issue:	Suppl. 1
Meeting Dates:	2018 Dec 1-4
Meeting Location:	San Diego, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2018-11-29
Language:	English
ACCESSION:	WOS:000454837601001
PROVIDER:	wos
DOI:	10.1182/blood-2018-99-112938
Notes:	Meeting Abstract: 292 -- Source: Wos